← Eichor
Study identifier: NCT06906900 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis

Condition: Spinal Metastasis  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 1
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This clinical research study is to learn about the safety of the NovoTTF-200M and Novo TTF-200A Systems, when used either alone or in combination with standard therapy, in patients with tumors that did not respond to treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Claudio Tatsui, MD  ·  (713) 563-8710  ·  cetatsui@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

The University of Texas M. D. Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06906900